Alprazolam
Alprazolam is the generic name of the Pfizer, Inc. brand named drug called Xanax®. It belongs to a general class of drugs which are active on the central nervous system. These CNS drugs are classed as benzodiazepines. These drugs are usually prescribed for treatment of specific psychological disorders classed as anxiety disorder, panic disorder, and a condition called anxiety associated with depression. Alprazolam acts as a depressant to the central nervous system.
Alprazolam has significant risk of induced drug dependence and can produce significant withdrawal symptoms including seizures. The drug is contraindicated for treatment of patients with acute narrow angle glaucoma, but may be used for patients with open angle glaucoma, as long as those patients are receiving proper treatment for their glaucoma. The risks associated with drug dependence associated with Alprazolam seem to be greater in patients being treated for panic disorder, as the dosage generally prescribed for this condition is above 4mg/day. Due to the risks of dependence and withdrawal, it appears that patients treated with this drug have a higher rate of a return of the symptoms associated with this syndrome, than those treated with placebo. There is even a danger of symptoms being more severe after treatment. Additionally, patients being treated with Alprazolam have reported
anxiety symptoms both in the morning and between doses of the medication.
Because this drug is a powerful depressor of the CNS, patients are warned to avoid occupations and/or activities which require high levels of function. There are also warnings of using this drug in combination with other CNS depressant drugs including alcohol. The nature of this drug and its effect on the central nervous system (CNS) is significant enough as to suggest that it should not be used by women who are in the first trimester of pregnancy, or who may become pregnant
due to the possible linkage of benzodiazepines with congenital abnormalities.
ALPRAZOLAM NEWS HIGHLIGHTS
- Cognitive Behavioral Therapy Best for Traumatized Youths
(HealthDay) - Cognitive Behavioral Therapy Best for Traumatized Youths
(HealthDay) - Voice Problems in Seniors Undertreated
(HealthDay) - Voice Problems in Seniors Undertreated
(HealthDay) - Voice Problems in Seniors Undertreated
(HealthDay) - Voice Problems in Seniors Undertreated
(HealthDay) - ADHD drugs cut risk of drug abuse, smoking: study
(Reuters) - Acorda Therapeutics Reports Date of FDA Advisory Committee Review of Fampridine-SR for Improvement of Walking Ability in People with MS
- Acorda Therapeutics Announces Positive Vote by FDA Advisory Committee for Fampridine-SR
- Acorda Therapeutics Announces Positive Vote by FDA Advisory Committee for Fampridine-SR
- Extended Therapy Helps Drug-Addicted Teens
(HealthDay) - Detox drug may help young addicts quit: study
(Reuters) - Personalized therapy best for kidney cancer
(Reuters) - FDA Approves Cymbalta for Maintenance Treatment of Generalized Anxiety Disorder
- FDA Approves Cymbalta for Maintenance Treatment of Generalized Anxiety Disorder
- FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
- FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
- Some Childhood Cancer Survivors Face More Challenges at
School
(HealthDay) - Some Childhood Cancer Survivors Face More Challenges at
School
(HealthDay) - Some Childhood Cancer Survivors Face More Challenges at
School
(HealthDay) - Some Childhood Cancer Survivors Face More Challenges at
School
(HealthDay) - Some Childhood Cancer Survivors Face More Challenges at
School
(HealthDay) - Some Childhood Cancer Survivors Face More Challenges at
School
(HealthDay) - Roche drug keeps patients cancer-free longer
(Reuters) - Drugs for depression, anxiety tied to preterm birth
(Reuters) - Roche drug keeps patients cancer-free longer
(Reuters) - COPD raises risk of depression: study
(Reuters) - Antidepressant Eases Anxiety in Older Adults
(HealthDay) - Cutting Parkinson’s Drug Dose Linked to Withdrawal Effects
(HealthDay) - Cutting Parkinson’s Drug Dose Linked to Withdrawal Effects
(HealthDay) - Drugs can help symptoms of borderline personality
(Reuters) - Most children recover from Lyme neuroborreliosis
(Reuters) - Nausea Drug Shows Promise Against Opioid Addiction
(HealthDay) - Nausea Drug Shows Promise Against Opioid Addiction
(HealthDay) - Glaucoma medications may reduce risk of death
(Reuters) - Certain Childhood Cancers More Likely to Recur
(HealthDay) - Certain Childhood Cancers More Likely to Recur
(HealthDay) - Certain Childhood Cancers More Likely to Recur
(HealthDay) - Certain Childhood Cancers More Likely to Recur
(HealthDay) - Certain Childhood Cancers More Likely to Recur
(HealthDay) - Certain Childhood Cancers More Likely to Recur
(HealthDay) - Quitting Smoking Tougher on Women
(HealthDay) - Quitting Smoking Tougher on Women
(HealthDay) - Interventional Ophthalmology Procedure Indicated For Treatment Of Glaucoma
- FDA Approves Concerta (methylphenidate HCl) Extended-release
Tablets for Treatment of ADHD (Attention Deficit Hyperactivity
Disorder) in Adults - Cymbalta Receives European Approval For The Treatment Of Generalised Anxiety Disorder
- FDA Approves Concerta (methylphenidate HCl) Extended-release
Tablets for Treatment of ADHD (Attention Deficit Hyperactivity
Disorder) in Adults - Breast Cancer: Risk Remains Years Later
- FDA warns of reactions to alcohol dependence drug
- New, Discrete-Angle Radiation Delivery Mode Extends Hi·Art(R) System Capabilities – Faster Planning And Treatment For Wide Range Of Cancer Cases